Drug intelligence / Profile preview

RS-1636

Development stage: Unknown
Lead developer: Daiichi Sankyo
Modality: Small Molecules

Overview

RS-1636 is a reversible dual monoamine oxidase (MAO) inhibitor developed by Sankyo (now Daiichi Sankyo). It belongs to a series of 3-(2-aminoethoxy)-1,2-benzisoxazole derivatives designed for the treatment of Parkinson's disease. The compound is characterized by its ability to inhibit both MAO-A and MAO-B subtypes, though it demonstrates a significantly longer duration of inhibition for brain MAO-B compared to MAO-A. This differential reversibility profile was intended to optimize the balance of monoamine regulation, potentially offering the therapeutic benefits of non-selective MAO inhibition while minimizing the side effects associated with irreversible or subtype-selective inhibitors.

Other names: 3-(2-(benzylmethylamino)ethoxy)-1,2-benzisoxazole

Targets

MAOA (Monoamine oxidase A)MAOB (Monoamine oxidase B)

Beyond the preview

Go deeper on RS-1636.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RS-1636.

Explore the full profile